Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting a green light in ultra-rare kidney disease C3 glomerulopathy (C3G).

Fabhalta was cleared for the same indication ... and rare kidney diseases C3 glomerulopathy (C3G) and idiopathic membranous nephropathy (IMN), along with PNH. Novartis itself is predicting it ...

Having a child recipient and helping someone in need – especially if they knew them – were among the top reasons that people ...

For this analysis, outcomes were compared between individuals who had pulmonary arterial hypertension (PAH) and healthy controls by using Fitbit-derived data over 12 weeks and then at a 1-year ...

At close: 5:29:56 PM GMT+2 ...